Millennium Management’s Cyclerion Therapeutics CYCN Stock Holding History

Millennium Management’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,887	Closed	-$16K	–	6189
2023 Q1	$16K	Buy	1,887 +76	+4%	+$959	﹤0.01%	5920
2022 Q4	$24K	Sell	1,811 -456	-20%	-$5.39K	﹤0.01%	5998
2022 Q3	$39K	Sell	2,267 -312	-12%	-$5.36K	﹤0.01%	6261
2022 Q2	$28K	Sell	2,579 -5,181	-67%	-$74.2K	﹤0.01%	6390
2022 Q1	$172K	Sell	7,760 -4,723	-38%	-$114K	﹤0.01%	5894
2021 Q4	$429K	Sell	12,483 -2,573	-17%	-$122K	﹤0.01%	5196
2021 Q3	$924K	Sell	15,056 -4,396	-23%	-$288K	﹤0.01%	4774
2021 Q2	$1.52M	Buy	+19,452	New	+$1.22M	﹤0.01%	4254
2019 Q3	–	Sell	-917	Closed	-$210K	–	4227
2019 Q2	$210K	Buy	+917	New	+$260K	﹤0.01%	3733

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management's CYCN Position: Q2 2023 in Review

Millennium Management sold out of Cyclerion Therapeutics (CYCN) in Q2 2023, closing a stake of 1,887 shares — an estimated $16K sold.

Millennium Management first reported a position in CYCN in Q2 2019 and held it in 9 quarters. The position peaked at $1.52M in Q2 2021. 18 funds tracked by Wall St. Rank hold CYCN as of Q2 2023.

Millennium Management reported no remaining Cyclerion Therapeutics position as of Q2 2023 after selling out during the quarter.
Millennium Management sold 1,887 Cyclerion Therapeutics shares in Q2 2023, an estimated $16K.
Millennium Management first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 9 quarters.
Millennium Management's Cyclerion Therapeutics position peaked at $1.52M in Q2 2021.
18 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.